Exploring the Immunoproteome for Ovarian Cancer Biomarker Discovery
2011

Exploring the Immunoproteome for Ovarian Cancer Biomarker Discovery

Sample size: 30 publication Evidence: moderate

Author Information

Author(s): Martin Karina, Ricciardelli Carmela, Hoffmann Peter, Oehler Martin K.

Primary Institution: University of Adelaide

Hypothesis

Autologous antibodies against tumour-associated antigens may serve as more sensitive diagnostic markers for ovarian cancer.

Conclusion

The study suggests that autoantibodies could be valuable for early detection of ovarian cancer, but further validation is needed.

Supporting Evidence

  • Autoantibodies are detectable at early stages of ovarian cancer.
  • Autoantibodies have a long half-life, making them stable markers in the blood.
  • Combining multiple biomarkers can improve diagnostic sensitivity.

Takeaway

Scientists are looking for better ways to find ovarian cancer early by studying antibodies in the blood that can signal the disease.

Methodology

The study reviews various immunoproteomic approaches for detecting autoantibodies against tumour-associated antigens in ovarian cancer.

Limitations

Many identified autoantibodies have not been validated for their diagnostic value.

Participant Demographics

The study involved patients with ovarian cancer, including those at various stages of the disease.

Digital Object Identifier (DOI)

10.3390/ijms12010410

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication